Skip to content
10-Q

Quarterly Report

PERSPECTIVE THERAPEUTICS, INC. CATX

0001193125-26-216790

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 114.05M sh
Shares Diluted Q1 2026 · Mar 31, 2026 103.6M sh
Shares Diluted Q1 2026 · Mar 31, 2025 72.36M sh
Capex Q1 2026 · Mar 31, 2026 $6.86M
Capex Q1 2026 · Mar 31, 2025 $4.66M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$31.47M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$21.58M
Long Term Debt Q1 2026 · Mar 31, 2026 $1.61M
Short Term Investments Q1 2026 · Mar 31, 2026 $216.96M
Short Term Investments Q1 2026 · Dec 31, 2025 $114.11M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $53.97M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $30.63M
Stockholders Equity Q1 2026 · Mar 31, 2026 $347.44M
Stockholders Equity Q1 2026 · Dec 31, 2025 $207.03M
Stockholders Equity Q1 2026 · Mar 31, 2025 $284.65M
Stockholders Equity Q1 2026 · Dec 31, 2024 $290.67M
Current Liabilities Q1 2026 · Mar 31, 2026 $31.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $28.68M
Total Liabilities Q1 2026 · Mar 31, 2026 $63.33M
Total Liabilities Q1 2026 · Dec 31, 2025 $59.94M
Current Assets Q1 2026 · Mar 31, 2026 $275.35M
Current Assets Q1 2026 · Dec 31, 2025 $148.39M
Total Assets Q1 2026 · Mar 31, 2026 $410.77M
Total Assets Q1 2026 · Dec 31, 2025 $266.97M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.25
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.25
Eps Basic Q1 2026 · Mar 31, 2026 −$0.25
Eps Basic Q1 2026 · Mar 31, 2025 −$0.25
Sga Expense Q1 2026 · Mar 31, 2026 $6.99M
Sga Expense Q1 2026 · Mar 31, 2025 $7.84M
Rd Expense Q1 2026 · Mar 31, 2026 $21.37M
Rd Expense Q1 2026 · Mar 31, 2025 $14.33M
Net Income Q1 2026 · Mar 31, 2026 −$26.19M
Net Income Q1 2026 · Mar 31, 2025 −$18.18M
Operating Income Q1 2026 · Mar 31, 2026 −$28.28M
Operating Income Q1 2026 · Mar 31, 2025 −$21.83M